ondansetron has been researched along with tacrine in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Doman, TN; McGovern, SL; Seidler, J; Shoichet, BK | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Giacomini, KM; Kido, Y; Matsson, P | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Harder, JA; Kelly, ME | 1 |
| Del Río, J; Diez-Ariza, M; García-Alloza, M; Lasheras, B; Ramírez, MJ; Redondo, C | 1 |
| N'Da, CI; Petzer, A; Petzer, JP | 1 |
| Eriksson, LA; Gholami, A; Minai-Tehrani, D | 1 |
12 other study(ies) available for ondansetron and tacrine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
Topics: Antifungal Agents; beta-Lactamase Inhibitors; Chemical Phenomena; Chemistry, Physical; Chymotrypsin; Enzyme Inhibitors; Kinetics; Light; Malate Dehydrogenase; Models, Molecular; Molecular Conformation; Scattering, Radiation; Structure-Activity Relationship | 2003 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
Topics: Drug Interactions; HEK293 Cells; High-Throughput Screening Assays; Humans; Kidney; Ligands; Models, Molecular; Molecular Structure; Organic Cation Transport Proteins; Organic Cation Transporter 2; Polymorphism, Genetic; Prescription Drugs; Protein Binding; Small Molecule Libraries; Structure-Activity Relationship | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
The effect of several putative cognition enhancers on a water maze acquisition deficit produced by pCPA + scopolamine combination treatment.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Cholinesterase Inhibitors; Cognition; Drug Interactions; Fenclonine; Male; Maze Learning; Muscarinic Agonists; Muscarinic Antagonists; Ondansetron; Oxotremorine; Rats; Scopolamine; Serotonin Agents; Serotonin Antagonists; Tacrine | 1997 |
Flumazenil and tacrine increase the effectiveness of ondansetron on scopolamine-induced impairment of spatial learning in rats.
Topics: Animals; Cholinesterase Inhibitors; Drug Therapy, Combination; Flumazenil; Learning; Male; Maze Learning; Memory; Muscarinic Antagonists; Ondansetron; Rats; Rats, Wistar; Receptors, GABA-A; Scopolamine; Serotonin Antagonists; Tacrine | 2003 |
The inhibition of acetylcholinesterase by dantrolene and ondansetron.
Topics: Antiemetics; Cholinesterase Inhibitors; Dantrolene; Erythrocytes; Humans; Inhibitory Concentration 50; Muscle Relaxants, Central; Ondansetron; Ranitidine; Tacrine | 2015 |
In silico and in vitro studies confirm Ondansetron as a novel acetylcholinesterase and butyrylcholinesterase inhibitor.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Humans; Molecular Docking Simulation; Ondansetron; Rivastigmine; Structure-Activity Relationship; Tacrine | 2023 |